Pacira BioSciences (PCRX) FY2018 results: revenue $337 million, up 17.7% on the year
Pacira BioSciences, Inc. (PCRX) reported revenue of $337 million for fiscal 2018, the year ended 31 December 2018, up 17.7% on the year before. Net income was -$471,000, and diluted earnings per share $-0.01. The figures are the company's own, from the 10-K it filed with the SEC on 28 February 2019.
Revenue
$337 million
+17.7% on the year
FY2011FY2018
Operating margin
4.7%
-8.7% a year earlier
FY2011FY2018
Net income
-$471,000
FY2011FY2018
Diluted EPS
-$0.01
FY2011FY2018
this yearthe year beforeHover a bar for its figure.
The year in brief
Income statement (profit and loss)
$ million
FY2018
FY2017
FY2016
On the year
Last 8 years
Revenue
337
287
276
+17.7%
Cost of revenue
86.8
87.9
110
-1.2%
Gross profit
250
199
166
+26.0%
Gross margin
74.3%
69.3%
60.2%
Research and development
55.7
57.3
45.7
-2.8%
Selling, general and administrative
177
161
153
+9.8%
Operating income
15.9
-24.9
-32.0
Operating margin
4.7%
-8.7%
-11.6%
Interest expense
21.9
18.0
7.1
+21.6%
Pre-tax income
-0.4
-42.5
-37.8
Income tax
0.0
0.1
0.1
-67.1%
Net income
-0.5
-42.6
-37.9
Net margin
-0.1%
-14.9%
-13.7%
Diluted EPS
-$0.01
-$1.07
-$1.02
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
FY2018
FY2017
FY2016
On the year
Last 8 years
Operating cash flow
48.9
17.8
33.5
+174.8%
Capital expenditure
14.5
19.3
24.7
-24.7%
Free cash flow
34.4
-1.5
8.7
Free cash flow margin
10.2%
-0.5%
3.2%
Cash from investing
20.6
-224
n/a
Cash from financing
9.0
224
n/a
-96.0%
Depreciation and amortisation
13.2
13.8
12.9
-4.8%
Share-based compensation
31.7
31.6
31.2
+0.4%
Diluted shares, weighted
41m
40m
37m
+2.8%
Shares outstanding at period end
41m
41m
37m
+1.4%
Balance sheet
$ million
FY2018
FY2017
FY2016
On the year
Last 8 years
Shareholders' equity
321
279
219
+14.9%
Debt
291
276
109
+5.2%
Operating lease liabilities
0.0
n/a
n/a
Other liabilities
77.5
72.7
63.8
+6.6%
Total liabilities and equity
689
628
391
+9.7%
Fixed assets
109
107
101
+1.5%
Goodwill
62.0
55.2
46.7
+12.4%
Intangible assets
0.0
n/a
0.0
Investments
277
317
137
-12.8%
Cash and equivalents
133
54.1
35.9
+144.8%
Receivables
38.0
31.7
29.9
+20.0%
Inventory
48.6
41.4
31.3
+17.3%
Other assets
22.7
21.7
9.9
+5.0%
Total assets
689
628
391
+9.7%
10-K for the year ended 31 December 2018, filed 28 February 2019: the filing.